ArticleSignal transduction and targeted therapy2020
Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial.
3 registry-linked trialsOpen access · goldAbstract readClinical Trial, Phase I
In one paragraph
Article in Signal transduction and targeted therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 218 papers, 18 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
218citing papers in PubMed, 18 pooled it
38.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT05787288 early_phase1unknown statusnot on this mapstarted 2023, after this paper: background citation
Clinical Study on the Safety and Efficacy of Mesenchymal Stem Cell Exosomes in the Treatment of Coronavirus Infection.
MATRIx: MesenchymAl Stromal Cells for Traumatic bRain Injury
NCT06492798 phase1 / phase2recruitingnot on this mapstarted 2023, after this paper: background citation
Effectiveness and Safety of Mesenchymal Stem Cell Therapy in Long COVID Patients
Who cites it
218 citing papers in PubMed, 18 syntheses or guidelines pooled it, 346 citations in OpenAlex.
- Therapeutic potential of mesenchymal stromal cells in COVID-19: a meta-analysis of clinical trials conducted since the pandemic onset.Stem cell research & therapy · 2026Pooled it
- Efficacy and safety of mesenchymal stem/stromal cells and their derived extracellular vesicles for acute respiratory distress syndrome: a systematic review and meta-analysis.Stem cell research & therapy · 2025Pooled it
- Efficacy and safety of mesenchymal stem cells therapy in COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials.Journal of translational medicine · 2024Pooled it
- Efficacy and safety of human umbilical cord-derived mesenchymal stem cells for COVID-19 pneumonia: a meta-analysis of randomized controlled trials.Stem cell research & therapy · 2023Pooled it
- Systematic review and meta-analysis of cell therapy for COVID-19: global clinical trial landscape, published safety/efficacy outcomes, cell product manufacturing and clinical delivery.Frontiers in immunology · 2023Pooled it
- Efficacy and Safety of Mesenchymal Stromal Cells Therapy for COVID-19 Infection: A Systematic Review and Meta-analysis.Current stem cell research & therapy · 2023Pooled it
- Updated Living Systematic Review and Meta-analysis of Controlled Trials of Mesenchymal Stromal Cells to Treat COVID-19: A Framework for Accelerated Synthesis of Trial Evidence for Rapid Approval-FASTER Approval.Stem cells translational medicine · 2022Pooled it
- Efficacy and Safety of MSC Cell Therapies for Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis.Stem cells translational medicine · 2022Pooled it
- Safety and efficiency of stem cell therapy for COVID-19: a systematic review and meta-analysis.Global health research and policy · 2022Pooled it
- Mesenchymal stem/stromal cell-based therapies for COVID-19: First iteration of a living systematic review and meta-analysis: MSCs and COVID-19.Cytotherapy · 2022Pooled it
- When stem cells meet COVID-19: recent advances, challenges and future perspectives.Stem cell research & therapy · 2022Pooled it
- Association between Mesenchymal Stem Cells and COVID-19 Therapy: Systematic Review and Current Trends.BioMed research international · 2022Pooled it
- Efficacy of umbilical cord mesenchymal stromal cells for COVID-19: A systematic review and meta-analysis.Frontiers in immunology · 2022Pooled it
- Pooled it
- Effectivity of mesenchymal stem cells for bleomycin-induced pulmonary fibrosis: a systematic review and implication for clinical application.Stem cell research & therapy · 2021Pooled it
- Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapy.Journal for immunotherapy of cancer · 2021Pooled it
- Stem Cells as a Model of Study of SARS-CoV-2 and COVID-19: A Systematic Review of the Literature.BioMed research international · 2021Pooled it
- Stem Cells Therapy for COVID-19: A Systematic Review and Meta-Analysis.Frontiers in medicine · 2021Pooled it
- Effectiveness and safety of normoxic allogenic umbilical cord mesenchymal stem cells administered as adjunctive treatment in patients with severe COVID-19.Scientific reports · 2023Trial
- Allogenic mesenchymal stromal cells and their extracellular vesicles in COVID-19 induced ARDS: a randomized controlled trial.Stem cell research & therapy · 2023Trial
158 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 3 institutions in 4 countries.
Fanping Meng *Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.
Ruonan Xu *Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.
Siyu Wang *Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.
Zhe Xu *Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.
Chao ZhangDepartment of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.ORCID http://orcid.org/0000-0001-8126-8145
Yuanyuan LiDepartment of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.
Tao YangDepartment of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.
Lei ShiDepartment of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.
Junliang FuDepartment of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.
Tianjun JiangDepartment of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.
Lei HuangDepartment of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.
Peng ZhaoDepartment of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.
Xin YuanDepartment of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.
Xing FanDepartment of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.
Ji-Yuan ZhangDepartment of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.
Jinwen SongDepartment of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.ORCID http://orcid.org/0000-0002-8582-8012
Dawei ZhangDepartment of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.
Yanmei JiaoDepartment of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.
Limin LiuDepartment of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.
Chunbao ZhouDepartment of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.
Markus MaeurerImmunotherapy Programme, Champalimaud Centre for the Unknown, Lisbon, Portugal.
Alimuddin ZumlaDepartment of Infection, Division of Infection and Immunity, University College London, London, UK.
Ming ShiDepartment of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China. shiming302@sina.com.
Fu-Sheng WangDepartment of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China. fswang302@163.com.ORCID http://orcid.org/0000-0002-8043-6685
Chinese PLA General Hospital · CNChampalimaud Foundation · PTUniversity College London Hospitals NHS Foundation Trust · GB
Funding
Ministry of Science and Technology of the People's Republic of China (Chinese Ministry of Science and Technology) 2017YFA0105703Ministry of Science and Technology of the People's Republic of China (Chinese Ministry of Science and Technology) 2018ZX10302104-002Ministry of Science and Technology of the People's Republic of China (Chinese Ministry of Science and Technology) 2020YFC0841900Ministry of Science and Technology of the People's Republic of China (Chinese Ministry of Science and Technology) 2020YFC0844000National Natural Science Foundation of China (National Science Foundation of China) 81721002
Abstract
No effective drug treatments are available for coronavirus disease 2019 (COVID-19). Host-directed therapies targeting the underlying aberrant immune responses leading to pulmonary tissue damage, death, or long-term functional disability in survivors require clinical evaluation. We performed a parallel assigned controlled, non-randomized, phase 1 clinical trial to evaluate the safety of human umbilical cord-derived mesenchymal stem cells (UC-MSCs) infusions in the treatment of patients with moderate and severe COVID-19 pulmonary disease. The study enrolled 18 hospitalized patients with COVID-19 (n = 9 for each group). The treatment group received three cycles of intravenous infusion of UC-MSCs (3 × 10
Indexed as
AdultAntibodies, ViralAntiviral AgentsBetacoronavirusCord Blood Stem Cell TransplantationCoronavirus InfectionsCOVID-19Drug CombinationsFemaleGlucocorticoidsHematopoietic Stem CellsHumansImmunoglobulin GImmunoglobulin MLopinavirMaleAntibodies, ViralAntiviral AgentsDrug CombinationsGlucocorticoidsImmunoglobulin GImmunoglobulin MLopinavirlopinavir-ritonavir drug combinationRitonavir
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.